Transcription of Reporting adverse drug reactions
{{id}} {{{paragraph}}}
BMA Board of ScienceReporting adverse drug reactionsA guide for healthcare professionalsMay 2006improving healthBMA Board of ScienceReporting adverse drug reactions : A guide for healthcare professionalsiReporting adverse drug reactionsA guide for healthcare professionalsMay 2006 Editorial boardA publication from BMA Science & Education department and the BMA Board of ScienceChair, Board of ScienceProfessor Sir Charles GeorgeDirector of Professional ActivitiesProfessor Vivienne NathansonHead of Science & EducationDr Caroline SeddonProject managerNicky JayesingheResearch and writingGemma JacksonEditorial secretariatEeMun ChenNicola FookesDarshna GohilEmily HoyAcknowledgementsThe association is very grateful for the help provided by the BMA committees and many outsideexperts and organisations.
reporting of adverse drug reactions (ADRs) is an important mechanism for post-marketing surveillance of medicines and is vital for maintaining drug safety. In 1996 the BMA’s Board of Science published Reporting adverse drug reactions – a policy document1, which discussed the different structures in place within the UK for reporting ADRs.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}